Sudeep Pharma Ltd: Stock Analysis & Fundamentals

Updated this week

Sudeep Pharma Ltd (Pharmaceuticals Bulk Drugs & Formulation) — fundamental analysis, earnings data, and key metrics. PE: 43.5. ROE: 32.8%. This stock is not currently in the Nifty 500 momentum outperformers list.

Key Numbers

Current Price

₹607

Market Cap

6.9K Cr

Valuation

N/A

Other Top Pharmaceuticals Bulk Drugs & Formulation Stocks Beating Nifty 500

Alivus Life Sciences Ltd

Average

+19.7%

← Back to Pharmaceuticals Bulk Drugs & Formulation Dashboard

Frequently Asked Questions: Sudeep Pharma Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Sudeep Pharma Ltd's latest quarterly results?

Sudeep Pharma Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: +65.5%
Revenue Growth YoY: +48.3%
Operating Margin: 35.0%

What is Sudeep Pharma Ltd's current PE ratio?

Sudeep Pharma Ltd's current PE ratio is 43.5x.

Current PE: 43.5x
Market Cap: 6.9K Cr

What is Sudeep Pharma Ltd's price-to-book ratio?

Sudeep Pharma Ltd's price-to-book ratio is 9.5x.

Price-to-Book (P/B): 9.5x
Book Value per Share: ₹64
Current Price: ₹607

Is Sudeep Pharma Ltd a fundamentally strong company?

Sudeep Pharma Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 36.0%

Is Sudeep Pharma Ltd debt free?

Sudeep Pharma Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹143 Cr

What is Sudeep Pharma Ltd's return on equity (ROE) and ROCE?

Sudeep Pharma Ltd's return ratios over recent years

FY2022: ROCE 36.0%
FY2025: ROCE 36.0%

Is Sudeep Pharma Ltd's cash flow positive?

Sudeep Pharma Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹49 Cr
Free Cash Flow (FCF): ₹-30 Cr
CFO/PAT Ratio: 35% (weak cash conversion)

What is Sudeep Pharma Ltd's dividend yield?

Sudeep Pharma Ltd currently does not pay a significant dividend (yield 0.00%).

Dividend Yield: 0.00%
Current Price: ₹607

Who holds Sudeep Pharma Ltd shares — promoters, FII, DII?

Sudeep Pharma Ltd's shareholding pattern (Dec 2025)

Promoters: 76.2%
FII (Foreign): 1.7%
DII (Domestic): 17.6%
Public: 4.6%

Is Sudeep Pharma Ltd a new momentum entry or an established outperformer?

Sudeep Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Sudeep Pharma Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Sudeep Pharma Ltd may be worth studying

Cash flow is positive — CFO ₹49 Cr

What is the investment thesis for Sudeep Pharma Ltd?

Sudeep Pharma Ltd investment thesis summary:

What is the future outlook for Sudeep Pharma Ltd?

Sudeep Pharma Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.